 |
|
HPPH
A lipophilic, second-generation, chlorin-based photosensitizer. Upon intravenous administration, HPPH selectively accumulates in the cytoplasm of cancer or pre-cancerous cells. When laser light is applied, a photodynamic reaction between HPPH and oxygen occurs, resulting in the production of cytotoxic free radicals and singlet oxygen and free radical-mediated cell death. Compared to the first-generation photosensitizer porfimer sodium, HPPH shows improved pharmacokinetic properties and causes only mild skin photosensitivity which declines rapidly within a few days after administration. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)
| US brand name: | | Photochlor | | | | Chemical structure name: | | 2-(1-Hexyloxyethyl)-2-Devinyl Pyropheophorbide-a | | |
| Previous: | HLA-A*2402-restricted URLC10-TTK-VEGFR1-VEGFR2 multipeptide vaccine, HLA-A1, A2, B35-restricted survivin peptides/Montanide ISA-51 vaccine, HLA-A2, A3-restricted FGF-5 peptides/Montanide ISA-51 vaccine, Hodgkin's antigens-GM-CSF-expressing cell vaccine, homoharringtonine | | Next: | HPV 16 E7:86-93 peptide vaccine, HPV L1 VLP vaccine V504, Hsp27 antisense oligonucleotide OGX-427, Hsp90 antagonist KW-2478, Hsp90 inhibitor AUY922 |
|
|
